APPEAR-C3G (2025) — Trial Summary

APPEAR-C3G (2025): The APPEAR-C3G phase 3 trial evaluated iptacopan, an oral factor B inhibitor, in patients with C3 glomerulopathy (C3G), the first randomized controlled trial to demonstrate efficacy in this rare complement-mediated glomerular disease.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.